Kraig Biocraft Laboratories Inc (KBLB)

[faithabides]

“20-30 million dollars in annual revenue.” From ASM

Currently, with 198.4m market cap, we are less than 10x future annual sales for just Quang Nam. We should be over 30x sales right now. ... We are being artificially held down by the RS 1 for 40 option fear.

https://www.fool.com/investing/2019/04/04/why-do-so-many-biotech-stocks-have-such-high-ps-va.aspx

The reason biotechs get such a high price to future sales is that there are such huge potential future profits from these drugs. The same holds for KBLB’s potential profit margins.

The low end is $20m x 30 = $600m. I believe someone said Bolt Threads last round of PE funding was a $600m valuation. I have been arguing for sometime that once KBL is in Mass Production they deserve this or better over Bolt Threads ‘maybe’. The market will need to catch up to this reality ... once financing and first delivery come that is where we go.


https://www.forbes.com/sites/amyfeldman/2018/08/14/clothes-from-a-petri-dish-700-million-bolt-threads-may-have-cracked-the-code-on-spider-silk/#5502ba08bda1